A Real-Life Study Assessing Long-term (7-Year Follow-up) Efficacy And Safety Of Omalizumab In Patients With Moderate-Severe Allergic Asthma

Trial Profile

A Real-Life Study Assessing Long-term (7-Year Follow-up) Efficacy And Safety Of Omalizumab In Patients With Moderate-Severe Allergic Asthma

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Mar 2017 New trial record
    • 06 Mar 2017 Results assessing the long term (up to 7 years) effectiveness and safety of omalizumab in patients with moderate-severe allergic asthma, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top